Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMP360 psilocybin therapy in anorexia nervosa
2021-006233-19Phase 2Completed
- Sponsor
- COMPASS Pathways
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of COMP360 in anorexia nervosa (AN) (2 arms), sponsored by COMPASS Pathways. Primary endpoints: Change from baseline in EDE global score at week 4 and Safety outcomes. Started May 2022; status: completed.
02
Drugs
COMP360
03
Conditions
anorexia nervosa (AN)
Beyond the preview
Go deeper on 2021-006233-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006233-19.